| Ytd | -36.65% | |
| 1y | -48.87% |
| Open | 2.04 | Prev Close | 2.04 | Low | 2.04 | High | 2.04 | Mkt Cap | 35.38M |
| Vol | 127.78K | Avg Vol | 170.82K | EPS | -6.93 | P/E | -0.29 | Forward P/E | -0.65 |
| Beta | 2.93 | Short Ratio | 3.85 | Inst. Own | 69.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.08 | 200-d Avg | 2.37 | 1yr Est | 16.33 |
MURA News
Mural Oncology PLC (NASDAQ: MURA - Get Free Report) has been given an average recommendation of "Hol
Shares of Mural Oncology PLC (NASDAQ: MURA - Get Free Report) have earned an average rating of "Hold
EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nas
WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mu
WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“Mu
WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MU
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION
WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq:
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & As
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Onco
Mural Oncology (MURA) Q2 Loss Widens 49%
Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximate
WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Iris
Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareho
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the
On Tuesday, Mural Oncology plc MURA released data from the ARTISTRY-7 phase 3 trial of nemvaleukin a
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mu
Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in plati
